Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability ...

A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

Dr Annalisa Morgan reflects on incorporating new treatments discussed at the 2025 ACTRIMS Forum into clinical practice.

inhibitors and the need for further research to refine treatment strategies and improve patient outcomes.

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to ...

Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL EP: 15 . Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences ...